由于GLP-1销售增长缓慢、竞争和重大重组费用,Novo Nordisk降低了2025年的预测。 Novo Nordisk lowered 2025 forecasts due to slower GLP-1 sales growth, competition, and major restructuring costs.

Novo Nordisk已降低其2025年全年预测,预测按不变汇率计算,销售增长8%至11%,营业利润增长4%至7%,分别从原来的8%至14%和4%至10%不等。 Novo Nordisk has lowered its 2025 full-year forecasts, projecting 8% to 11% sales growth and 4% to 7% operating profit growth at constant exchange rates, down from previous ranges of 8% to 14% and 4% to 10%, respectively. 修订的原因是,由于Eli Lilly和通用专利的竞争日益激烈,GLP-1型肥胖症治疗比预期增长慢,加上与全公司转型挂钩的结构调整成本约为90亿丹麦克朗。 The revision stems from slower-than-expected growth in GLP-1 obesity treatments due to rising competition from Eli Lilly and generics, along with about DKK 9 billion in restructuring costs tied to a company-wide transformation. 尽管在头九个月丹麦克朗的销售额增长了12%,按固定货币的销售额增长了15%,但该公司指出,当前的市场挑战和领导力变化,包括新的首席执行官,是影响其前景的因素。 Despite a 12% sales increase in Danish kroner and 15% at constant currency in the first nine months, the company cited ongoing market challenges and leadership changes, including a new CEO, as factors affecting its outlook.